CINXE.COM

<!DOCTYPE html><html lang="en-US"><head><title>Just a moment...</title><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta http-equiv="X-UA-Compatible" content="IE=Edge"><meta name="robots" content="noindex,nofollow"><meta name="viewport" content="width=device-width,initial-scale=1"><style>*{box-sizing:border-box;margin:0;padding:0}html{line-height:1.15;-webkit-text-size-adjust:100%;color:#313131;font-family:system-ui,-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji}body{display:flex;flex-direction:column;height:100vh;min-height:100vh}.main-content{margin:8rem auto;max-width:60rem;padding-left:1.5rem}@media (width <= 720px){.main-content{margin-top:4rem}}.h2{font-size:1.5rem;font-weight:500;line-height:2.25rem}@media (width <= 720px){.h2{font-size:1.25rem;line-height:1.5rem}}#challenge-error-text{background-image:url(data:image/svg+xml;base64,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);background-repeat:no-repeat;background-size:contain;padding-left:34px}@media (prefers-color-scheme:dark){body{background-color:#222;color:#d9d9d9}}</style><meta http-equiv="refresh" content="390"></head><body class="no-js"><div class="main-wrapper" role="main"><div class="main-content"><noscript><div class="h2"><span id="challenge-error-text">Enable JavaScript and cookies to continue</span></div></noscript></div></div><script>(function(){window._cf_chl_opt={cvId: '3',cZone: "aacrjournals.org",cType: 'managed',cRay: '8e6e4c90bbb95fc6',cH: 'kZStFVJjgN2xQi4jkcQ69rm7C8ZmcFLFi57d1pi8VYc-1732334917-1.2.1.1-VrPVoGKTo5zgxQZncDRKxUBCGt01tLbQgCBR4He83m7h89sKMQT5nGu3.xbiPQBZ',cUPMDTk: "\/cancerres\/article\/67\/12\/5821\/533044\/Tumor-v-3-Integrin-Is-a-Therapeutic-Target-for?__cf_chl_tk=P2f9Y9UurjswIG2VVr9BQEz7iRmcZJwVze5DkMJJdSM-1732334917-1.0.1.1-3U3rKHliPRJ7AQ8R8Qt96IMVKJU263n_qG7FqqsGYc4",cFPWv: 'g',cITimeS: '1732334917',cTTimeMs: '1000',cMTimeMs: '390000',cTplC: 0,cTplV: 5,cTplB: 'cf',cK: "",fa: "\/cancerres\/article\/67\/12\/5821\/533044\/Tumor-v-3-Integrin-Is-a-Therapeutic-Target-for?__cf_chl_f_tk=P2f9Y9UurjswIG2VVr9BQEz7iRmcZJwVze5DkMJJdSM-1732334917-1.0.1.1-3U3rKHliPRJ7AQ8R8Qt96IMVKJU263n_qG7FqqsGYc4",md: "HkIfLOtQDhqRgzaxXkAV3od0T.vZsE6mNenD7xWP_Bw-1732334917-1.2.1.1-76vdoFA153HQ5VjopKRndquEFf09q6B1dWPYpugv_27R8h4_aawl6bAHtD7GjOuLumPn1bsXMQJouiS8cTOVFsWnoM4y90o0bcy3yLLqeLseCS.n5udNu1nizj48jW8SdEXkgxasQRFtc_Sq35WY.HeAig72.TxoA766HFP2WY8jldh6cyq2psRoa0wYSxzC5SPZoGvu7PBDfsNCd4nTcmaE8.Sde5l2jK5hf5E0snqBWsiQTMfuA7hjmtbiwW6mIt3n5.uBpEu4C26WHSBq5v94FC7DlGrplHAmXdLk6fDnAi3c1lPlGJNMKKjVME6n7MfyGF0LjsRX5jzxB4ueMDOaW68eIrP9zX7txSA2mpnc9TGTcCblqLG4N2cuYxIBWNonZ1UmwyY71U_mrmwbM4l7eRwvl4H5j5xWt9dSk5LLZCGd9VHNTWxtXlzni.g0s1_u28f2xq7MQfKa.sY6lUYovuC24tGhJGyBFGy4._vBJl_p_RCqGIbkt0kV16DrmtbaC8OrDCyWtukcaH0jXhfrw2CyFjUMCumb8WY1bEue.NpoobwV13TQrb9wfWHbOTsNm9xQIX4FonLzRFiKVe5k3seUJo9FKQYysHtYLDetSGjWdrvU0cLk.A9jciUOM6RBKAHuYcvysBBTMdpLqgW_dVHUW7FFry7vyrm00Ub5d95mCFjKqtPra6gI2JErz5m0rv.NiOJJxnCR7FaAfRyt9l13X.fdwErMe7q9D16JEcyujiWD5cjXOHeyfl.Rj7vbAnvW.0Ur8uO6U8p1537Nijn9HfNQOuEmTh0lrBPYtlOEmtk0MmNoLN2giy4JIEbMaLPmjjKO.clRnDFk3LcuItbXBp06TsC4Nf7pwihqQTgeiRCC_tcuZIjqeQbscom59FWlQFZMpShGwAJB_.r2F.NcqEnehGNVO43fwwTQJa1X.JZQZWQKKeDcqiMkyvv0sR4M.rI7q5eCFrbf_XX9sHjsNb6RpfveFpcF25Vh4WtI3YZX.gJSXDUrAc526.rBubIFzRd.eMzZBX_hznZiR4XvqqdyknSVtjJ4TsID_Eag25ke6taW862alM4tDyHS3o2JN51e1zhdqVm7YiLx2kOGVtNnfXvd_mRHyLBZLVwAKO5qS7DKXOgdkoX5MMy.DTNRlbItZ5Q7_0I0NGPTRTpVkifzMWnSd_RdBu_juPaN4zCfRgQyYLXS7.aUrHB4lJYHnEeDwV5d1kaH149zh2DSBf2zwE.5u3_hTiRdrdwJom.w2EJaE1_3a6OxHc2PFAELsvnjVrOnlgOCqN3LcDD9Fw9tkCtOqkN7QVyPqvBWVV2Ql_5gnLMDkiJ94RRV7X3C_tQfrDlBh_P_MBIx4qinrt4FfspSGRbNkHit.y4m6tKW93RstI__MFWoinoyzjLtt58CpYxbnzcCsl6wr8t.Y1tp8PrHfmctNYbtcIFa9Oj0SlRpjbuJz0QiQtYhbRtlb1mg6vsb5oySFZaI9YnBuYXdM_NW.ih4s3ebuzZNw6kErdhZR4jXhQI.4_7EVfVLr_iXiFEnXjMnPDvpwtVRMxESAPoikNU46IGyyJWwUqjj_FLFMY.kPMvRShVK2WcSeGlHUyemsdDaWnYr3gXpUwEQPhdaRhqkSx7d_tx9jcHrskJBun2NUmD1rr.6V66IavNuCuI4vp3RscLd4hSssoY2kx.zjHMsedjPDPsBqp4QUjQJzvBz_oLPfAbusQW5WZh8fQF0zqqQQr_pbCiA5uhaKFI.7tQlCSVayWpIutCqyil2gprQTQLmqBU7vPVhsUAxFj1s7NI.R8ohMmXTai.T2BHf314Cb6Zc.GRizyTgSSLUZVPZ.0PFX135VyiimLC45iOod44Xl5JqBsVsxBLnUCkDFM_zQfDA6FRc7kGwuyQUU2MnodiGeWa4kB1cRDQHu0PBGEY9ODhnIkkG3N38k_m3jL.ABo1kho4nQOimicLJC4D1pxlX3GDA3Q_fcMdZrbJWjeKwfgpOQcZ4RFNUSkeUm9cxUIWirkLPALB8Rr5N5_X5lW56T6Xt.soU9pbNPefyLAeFxDyQB80Hv6AcdNCyUEsYmEzhag8iL0vh1Qt980t9.4cJUZwCbcq4e23Ff.d8r8SwdGKIa3zGud2t3HOT_X8QZNnkiNWS9yDCBpQxVuVA9JPbVR2FTDvwgKUNUK4ZiQvXUebpt2j35JPaLhcA0z9CC.ZTFR812VbhsiIBmreCuxkun29x9XBOQX1cCxvjAF11aq558ZEMs9eCviqNFcIhS_R9tiMMk7jMPiF9M9TkuAgn7YXWE0H0OFZ4tl8S9b8xIcys3tz3_GW.gqZMB.dLSH7xh1QwYaxBV6UF5__rlXo8Y62YBZe3Xr3g82.nSh5UUJmHqPVQRHGYRgTAVrWrqYh3KTUp9hMsJLbRmcuM3YMSgDpxaehTmSZqzajAnvi3ym2KWsEZI6RnOR_AdDyyohRFLZOnM1Ot_89U_ycwqm5XiO0sUWfgcZT3W6_vFHTU6PBH3XlekQkNA8LAFF4gIPLax1lIJw2.lfI7u14zExSd4H9px7BBT.2j7z1sWJzLpjPprSFtyno_rXnoawpb4ltFY5udfoOQjPWYENCr0YHcvdZFF9qVj9c60.9EMyFttAHhbSYSDheDwmXDf.HPL9Aq_8MIb7bT52aHRZksYc4nZCIQDfPi_X8GdkcON8m5grkpWijQ9OPPfBhSho_Qyst_QY_1lnhNCxCZXsV5neRcThlAt47ynBf0ekNld.FyRfjaKm_B03LmF8kxdycwZirJuOhAm3.HH0Q1h.TyC6YMf_w.fF5vfQ7q0ssQ.gBBzpOsPVDKMIjmZbBWk9rhFLQHmiCeVisJT3ChZ3inF11aJxxkydqdAYuaFr4lq8Blnd.TYddt7pC3wO9lmZou.L.URkWrAsjpS5L8mM80PAbjYNuthcqbtaRoa_FUKydr27E_bpDEu7w76GvkC7cQnxEJ.v4o0yiyRwX5F5T2ias9L8cNDcME9Al8gUQvxn4b7QbUQBS76sNvJb6Llc5f1bIuI3hvV4M4kHP7UGgopP_6rgGlIqnXNmX7BhRmvR_Ky_ke.wUlBkqoLi_jCcUCrCX1D88blBU2WMyKisO9FInX",mdrd: "V0uIgjyhHiaoQjf.dP7tZW5a4fCJd1RfZp._gmkMhpw-1732334917-1.2.1.1-5en9yVTfohqbUdq5qrtxkF3hKiqdC13wRLv9ed3b_G0ZQBvsHPZ_IVCtvbec1vPt4TqOxlCxIpH8t9mxawcMYySqyo4jm.p1YB0KrUIiBl1.5N1CUAQEtGoWnxz6QDXL3.xfnnNoLnp7OcY3roeO_OesdM6lDLu626EWU1zOy1OViJvQFqVocYSBO0TdNFFA_sjxiKIUGTCXauPl7gIl.9Q8ibv8mTDRtv85PHXSq595UWPO7cfxNHMentN.B3FNvkgg8apoDS.YVNjmMe11Pj9ldljvfgEtWr6Ldu9zXQAbb3GMPaY_CGBdAP8ES2HlL45VZW4NWtnVOr3Q6tCVMvytAvV4QSymieBq5oV63sk2XstH0rd9AXBTwA7dNJOF2SxGzo9i.7Fs1PTrMQF94Ls61jmF7wwhAFnsjIDhpclVt1Y2YKGaU4FdtE1l3.n8Hi1j7l7uoF4cyunPdUvGiEfIGNETD0Yo8Ior_Ge6TdMvqOmIEO458ifEG_YNdEvWSA7wzoixGUMh5bTrNpxGuS5bjoN3kB9VCN_QIOFTeq3D1_cdZAwqbJ_uIqOTNz_SjGBDlbO_IoV7djbY4dxeRD0TcEMIEf_R5zrRg.pjt5b37ij0UC6iv1bJ26VRHOzOdZ0sW4D0aeFUbaS5MTyWN8.5EXOvjTez9sI4Ios1wuyoUmMX41TgHqi7Ouh0cAxkX3jg9nq0J1h.21cUFPbBc7SB0UI0SIfZ2X9ocT82_mSPhMFDqj1nxQ9F8tyVidGSYNh.KRbywfQQKpbNneiHm_dO0KYNdUAq4AvDs3FBXuZO22s._1_7CowCZlHIY7LCpVQwrG0ydbCg0KBJNO8PGuvL4Rm2BFUx8DzuuMYues4qq5bwFsCR2I8N7gQraf5zJ8mruTity4AtgTH1GCA6TJ6jNT5Latrcq4zHju8xwf0aB472tVksjLtBlEm1ySWSlgW5lp0Il_gJemQ6UNR4tcqlATV6aUTUoetjvdDzMRG07.hwVsu7GddwHrb.DQ382kmgZvxBtnj1SDbFC0opqAY.w367lFyAsy5mNkez54qzb8BobdrHXziZCYw_cube4il7niZ0NYsMqochwb2a.Puydt2CNlI_mA3Pcm7qr_nkhS7iAH8iuXunBoJoAsSxaOeFRb401fxt7Y9BnvPPZ9fdEOcxfNMlajSI3l5QMFB70AQgQob7SPNAN0UWnANkID4rn3JHMcxKg8YLRtGQ8m0LW_jhgQTmYhb6prLy_WN3WG9D_HrFmypGLlf9SG3SAJOHfmLgfko508CTLy7Ic6xC68IojwyIAEcHPcCfoALwqTVGJpmNNzOf5zo2c6F046exFezMkr_kEQnq6DSn8N7iKSMUAO5gC4HPKcfPzPJT04sbHbAGraLz6J3dlvg8l7Nypj1S68.NZkdzhWEQ4l2fzc9i1KFTwYD7c9sBwiRhSqRQmjIGArwg3_WwHIAR0Gnl7.gPMrpmI5QatTzZ1hEP.tPNJZM97ESoviB9MJnVSvGHle5hjF1YTR68uevaraZApIXbFnWL.DGBOaZ5xDxApq9z5rSDJ.11WhJ3hNgRHyj1r5kzH0.XIgUuhZAraYHzuXEtjaLuh4c.BMbj8PJvTf9YvB3P0nLftN..WfOCS2EeyXwKZP_uR0qmOWMCbW3mZzcc189dX8re_igFo53FCoi_M017aZKEnPWWCunVfLp55FVi57Y6BKgQDGjyWgZHZYjFBcePcBOXlxRavJ13R9lOufrGyvfkXPNJUfnmaJtapSGfkVfW5kC4l_mxsV.t9a38gw01l9dU1aXBbqWLqFvMLEj1qM74DIPQxZGeGfseW_m4aVWR7YgZ_oRTM35p9K5jN9APP2L_OVz6rPFHS50dQDE2psiCKm8igeNVk4BaRvSHNTQ50yJjX8R9Jlh6elTze7PFoX7Ex0Kl9DfH9HqG6KD5UuvO6sjqujwt_thSVBQ9DmUqciXrde.T"};var cpo = document.createElement('script');cpo.src = '/cdn-cgi/challenge-platform/h/g/orchestrate/chl_page/v1?ray=8e6e4c90bbb95fc6';window._cf_chl_opt.cOgUHash = location.hash === '' && location.href.indexOf('#') !== -1 ? '#' : location.hash;window._cf_chl_opt.cOgUQuery = location.search === '' && location.href.slice(0, location.href.length - window._cf_chl_opt.cOgUHash.length).indexOf('?') !== -1 ? '?' : location.search;if (window.history && window.history.replaceState) {var ogU = location.pathname + window._cf_chl_opt.cOgUQuery + window._cf_chl_opt.cOgUHash;history.replaceState(null, null, "\/cancerres\/article\/67\/12\/5821\/533044\/Tumor-v-3-Integrin-Is-a-Therapeutic-Target-for?__cf_chl_rt_tk=P2f9Y9UurjswIG2VVr9BQEz7iRmcZJwVze5DkMJJdSM-1732334917-1.0.1.1-3U3rKHliPRJ7AQ8R8Qt96IMVKJU263n_qG7FqqsGYc4" + window._cf_chl_opt.cOgUHash);cpo.onload = function() {history.replaceState(null, null, ogU);}}document.getElementsByTagName('head')[0].appendChild(cpo);}());</script></body></html>